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Summary 
A 12-year-old male neutered Miniature Poodle with confirmed pituitary dependent 
hyperadrenocorticism was treated with trilostane. After three doses it developed clinical 
and laboratory changes suggestive of isolated hypocortisolism (‘atypical 
hypoadrenocorticism’) which persisted and progressed for more than 3 months despite 
immediate withdrawal of the trilostane. The clinical signs of hyperadrenocorticism 
resolved without further trilostane. After 3 months prednisolone treatment was started 
and the clinical signs of hypocortisolism resolved. Prednisolone therapy was required 
for more than 1 year. Ultrasonography initially demonstrated large hypoechoic adrenal 
cortices, typical of dogs with hyperadrenocorticism which then became small and 
heteroechoic, consistent with the development of adrenal necrosis. Persistent isolated 
hypocortisolism has not been reported previously as a complication of trilostane 
therapy. The case is also remarkable for the very short duration of trilostane therapy 
that elicited this complication. Clinicians should be aware that trilostane therapy may 
result in adrenal necrosis even in the very earliest stages of therapy but prompt action 
can prevent a life-threatening situation. 
Abbreviations used 
ACTH  Adrenocorticotropin 
HAC  Hyperadrenocorticism (HAC)  
IV  Intravenously 
LDDST Low dose dexamethasone suppression test 
MUVH  Murdoch University Veterinary Hospital 
PD-HAC Pituitary dependent hyperadrenocorticism 
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SC  Subcutaneously 
UK   United Kingdom 
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 Trilostane is a synthetic, hormonally-inactive, steroid that competitively inhibits steroid 
synthesis by blocking the action of 3β hydroxysteroid dehydrogenase. Trilostane has 
been found to be an effective treatment for dogs with pituitary dependent 
hyperadrenocorticism in several published trials totalling more than 120 dogs.1, 2, 3 
Current evidence suggests that its principle effects in the dog are on cortisol secretion: 
aldosterone production is relatively unaffected.4 The median survival time of dogs 
treated with trilostane is not significantly less than that achieved with mitotane.5 Minor 
side effects are sometimes seen with trilostane, such as mild lethargy, decreased 
appetite and slight electrolyte abnormalities.1 However the incidence of side effects in 
these studies (15%) was lower than that reported with mitotane (25%).6 
Hypoadrenocorticism is only rarely seen during trilostane treatment (3 % of treated 
cases) but is more common during mitotane treatment (5 to 17% of treated cases) .6, 7 
Trilostane’s mechanism of action suggests that it would not be expected to cause 
permanently low cortisol levels (hypocortisolism). Any endocrinological abnormalities 
induced by trilostane should dissipate rapidly following withdrawal of the drug. In the 
largest published study to date of 78 dogs receiving trilostane, hypoadrenocorticism 
was confirmed in two dogs, one of which resolved after trilostane was withdrawn1. A 
further two dogs died of unexplained causes shortly after starting therapy.  
Recently a case was reported in the UK of a dog that developed severe adrenal 
necrosis and hypoadrenocorticism following a 21 day course of trilostane8. In this short 
communication we describe an Australian dog with PD-HAC that developed isolated 
hypocortisolism and ultrasonographic evidence of adrenal necorosis after only three 
doses of trilostane. This is the first report of permanent isolated hypocortisolism 
associated with adrenal changes in a dog treated with such a brief course of trilostane. 
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Isolated hypocortisolism is sometimes referred to as ‘atypical hypoadrenocorticism’.  
Veterinary practitioners should be aware of this potential, though rare, side effect of 
trilostane therapy. 
Case report 
A 12-year-old neutered male Miniature Poodle was initially presented to the emergency 
service of Murdoch University Veterinary Hospital (MUVH) with a history of frequent 
vomiting over the previous 8 hours and a longer history of recurrent intermittent 
vomiting and diarrhoea over the past few years with the last episode being a month 
previously. The vomitus consisted mostly of food; bile and blood were not present. On 
clinical examination, the dog was noted as being obese and had partial truncal 
alopecia. Further questioning of the owner revealed a 1 year history of polyuria, 
polydipsia and marked polyphagia. There had also been an episode of dermatitis in the 
previous year. Routine blood samples at the referring practice had been obtained 1 
week before this episode and analysed using an in-house analyser. There was a 
marked increase in alkaline phosphatase (AP) (1393 IU/L [reference range is 23 to 212 
IU/L]) and alanine transaminase (ALT) (200 IU/L [reference range is 10-100 IU/L]). 
These changes were felt to be consistent with hyperadrenocorticism although an 
association with of the previous illness could not be discounted. Blood samples were 
taken on admission to MUVH for electrolytes, a packed cell volume and total solids 
(assessed by refractometery). The results were within reference limits. An ultrasound 
examination of the abdomen was performed. The liver was subjectively enlarged with a 
mild, diffuse increase in echogenicity suggested by the fact that portal markings were 
just visible. The left and right adrenal glands were plump in appearance though both 
retained their normal shape (see Figure 1). Both adrenal cortices were hypoechoic. No 
other abnormalities were detected, and importantly the pancreas appeared to be 
normal. These changes were considered to be consistent with pituitary dependant 
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hyperadrenocorticism.9 No cause of vomiting or diarrhoea was evident and no specific 
diagnosis was made. The dog recovered well with symptomatic therapy (intravenous 
fluids, ranitidine 2mg/kg IV twice daily and one injection of methadone 0.3mg/kg SC). 
The vomiting resolved 9 hours after admission and the dog was discharged back to the 
referring practice with advice that the long history of polyuria/poydipsia and polyphagia 
should be further investigated.  
The dog was then diagnosed 1 week later with hyperadrenocorticism (HAC) using both 
the adrenocorticotropin (ACTH) stimulation test and the low dose dexamethasone 
suppression test (LDDST). Cortisol concentrations were measured in a local 
commercial veterinary laboratory (VetPath, Ascot, WA) using a solid phase competitive 
chemiluminescent enzyme immunoassay (DPC Immulite Cortisol assay, Diagnostic 
Products Corporation, Los Angeles, California) the results of which have been shown 
to be well correlated with the results of radio-immunoassays previously validated in the 
dog.10 The ACTH stimulation test showed evidence of moderate overstimulation with 
cortisol concentrations increasing from 96 nmol/L to 806 nmol/L. Greater than 600 
nmol/L is considered to be consistent with the diagnosis of HAC.11 During the LDDST 
the cortisol concentrations were initially 117 nmol/Lwith moderate suppression of 40 
nmol/L at 4 hours post-dexamethasone and escape of suppression by 8 hours-post 
dexamethasone with levels rising to 64.9 nmol/L. Greater than 40 nmol/L is considered 
to be consistent with the diagnosis of HAC.11 The results also strongly suggested that 
the condition was pituitary dependent.11 As the acute vomiting episode was less than 
24 hours in duration and 1 week had elapsed between the previous episode of illness 
and these endocrine tests, the effect of the illness was not likely to have had significant 
impact on the results. The existance of clinical signs and routine blood tests that were 
consistent with HAC before the development of the acute vomiting episode lend further 
evidence that the results of the endocrine tests could be taken as confirmation of HAC. 
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The dog was started on treatment for hyperadrenocorticism with trilostane 6 weeks 
later, obtained from a compounding pharmacist in Australia, at a dose rate of 5 mg/kg. 
However, after only three doses (60mg each) had been given to the dog, it was 
presented to the MUVH emergency centre with another episode of vomiting and 
diarrhoea; this time it was systemically unwell. On clinical examination there were no 
changes from previous examinations except the dog was dehydrated. The PCV was 
0.55 L/L and total solids measured by refractometery were 90g/L. The sodium 
concentration was 137 mmol/L and the potassium was 4.7 mmol/L when measured on 
a hand-held emergency analyser (i-STAT, Heska Corporation, Fribourg, Switzerland). 
The dog was given small quantities of an oral rehydration solution (Lectade: Jurox Pty 
Ltd) and two doses of metoclopramide (0.3mg/kg SC). The dog’s condition improved 
quickly and it was discharged the following day without further investigations.   
Trilostane treatment was stopped by MUVH emergency centre and the dog’s condition 
improved temporarily. However, when the dog was presented 3 months later to the 
medicine service at MUVH, the owner reported intermittent bouts of vomiting and 
diarrhoea, as well as the complaint that the dog was licking its legs a lot more and was 
refusing normal food on a regular basis. There was no evidence of polyuria or 
polydipsia. There had also been a weight loss. The dog had weighed 12 kg but now 
weighed 10.5 kg. Body condition score at this time was 6 out of 9.  
On clinical examination, it was noted that the coat was regrowing and there was saliva 
staining on both forelimbs and paws, suggesting pruritis. These findings, in 
combination with the lack of appetite, led to a suspicion that the dog no longer had 
HAC and was in fact suffering from hypoadrenocorticism. A serum biochemistry panel 
was measured using a fully automated clinical chemistry analyser (Rx Daytona; 
Randox (Australia) Ltd., Parramatta, NSW) which demonstrated that the AP 
concentration had declined to 77 iu/l. This would not be expected in a dog with HAC 
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that had not been treated in 3 months. No electrolyte abnormalities were identified 
(sodium was 139 mmol/L (reference range =  to ) , potassium was 5.1 mmol/L 
(reference range =  to ) (the Rx daytona uses ion selective electrodes). An ACTH 
stimulation test demonstrated that the pre and post ACTH cortisol concentrations 
(measured by the same method and in the same commerical laboratory as described 
above) were 25.8 and 26.5 nmol/L respectively. Abdominal ultrasonography 
demonstrated that the liver remained subjectively moderately enlarged with rounded 
borders and a mildly echogenic uniform texture. The portal vasculature was more 
visible than on the previous examination and the liver was less echogenic than the 
spleen. This suggested that the changes in liver echogenicity associated with 
hyperadrenocorticism were less marked. Both of the adrenal glands had reduced in 
size.  The left adrenal gland had lost it's normal ‘kidney’ shape and was irregular in 
appearance with a mottled, mixed echogenicity. It was surrounded by a small rim of 
bright echogenic fat.  The right adrenal gland was more difficult to image however it 
was more uniform in texture and echogenicity.  The surrounding fat was normal in 
appearance. The appearance of the adrenal glands was felt to be consistent with 
adrenal necrosis with some evidence of periglandular inflammation on the left. The 
concentration of aldosterone was measured in the pre ACTH sample (which was also 
the sample used for the serum biochemistry reported above) by a local human hospital 
using a commercial human radio-immunoassay (DPC Coat-A-Count Aldosterone 
assay; Diagnostic Products Corporation, Los Angeles, California) and was found to be 
less than 70 pmol/L. No reference range for canine serum has been validated by this 
laboratory however the published ranges for pre-ACTH aldosterone concentrations in 
canine samples measured using similar human assays is 0 to 300 pmol/L.12 In the 
absence of electrolyte abnormalities it was felt that there was no evidence of 
mineralocorticoid defiency and therefore no specific mineralocorticoid treatment was 
prescribed.  
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The dog was treated with prednisolone (0.5 mg/kg orally once daily) for 2 weeks and 
responded very well. Within 24 hours its appetite had returned to normal, it had shown 
enthusiasm for exercise and was generally more active. The dog remained well for 3 
months after which the dose of prednisolone was gradually tapered. Within 7 days of 
stopping prednisolone the dog developed signs of hypocortisolism again and an ACTH 
stimulation test was repeated. The pre and post ACTH cortisol concentrations were 
22.7 and 22.4 nmol/l respectively. Prednisolone was restarted and the dog recovered 
and remains well (although is still receiving prednisolone) a further 12 months later. 
Several attempts were made to reduce the prednisolone dose during this time but each 
time the dog became unwell (lethargic). Electrolytes were rechecked once in this time 
and were found to be within the reference ranges. 
Subsequent analysis using high pressure liquid chromatography of the trilostane 
capsules obtained from the compounding pharmacist confirmed that they contained the 
correct dose with minimal quantities of ketotrilostane.  
Discussion 
The diagnosis of PD-HAC was confirmed in this dog using the widely accepted criteria 
of appropriate clinical signs and response to specific endocrinological tests.11 The 
subsequent regrowth of hair, reduction in polyphagia and loss of body weight would be 
consistent with successful trilostane treatment. Occasionally steroid–responsive clinical 
signs, such as pruritus, may be unmasked in dogs treated successfully for HAC. The 
recurrence of a pruritic condition in a dog following trilostane treatment has been 
observed by others.11 However, the clinical signs of lethargy and vomiting that this dog 
developed are not consistent with successful trilostane therapy and would be 
consistent with overt glucocorticoid deficiency.13, 14 Moreover, as sodium and potassium 
concentrations remained normal, suggesting an adequate aldosterone concentration, 
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this dog appears to have developed isolated hypocortisolism, also known as atypical 
hypoadrenocorticism. The fact that the clinical signs did not resolve in the 3 months 
following withdrawal of the drug, but did respond to prednisolone therapy, suggests 
that this isolated hypocortisolism was a persistent state rather than temporary state. 
The withdrawal of the therapy 3 months later and the immediate recurrence of the 
signs is also evidence of the persistence of this hypocortisolaemic state.  
The cause of this isolated hypocortisolism is most likely to be selective or partial 
adrenal necrosis although no adrenal biopsies were obtained in this case. The changes 
in the ultrasonographic appearance of the adrenal glands are highly suggestive that 
this is the explanation. The ultrasonographic appearance of the adrenal glands in this 
case are in marked contrast to those described for dogs that are treated for extended 
periods with trilostane.15 It could be argued that the clinical signs may have been 
caused by another disease rather than overt hypocortisolism.  However no evidence of 
another disease was found on routine blood screens or abdominal ultrasound 
(specifically including the pancreas). 
This case has some similarities to one recently reported in the UK8. The dog in this 
earlier report developed bilateral adrenal necrosis and associated clinical signs of 
hypoadrenocorticism after 21 days treatment with trilostane. Electrolyte abnormalities 
were identified although aldosterone concentrations were not measured. In contrast, 
the case reported here developed isolated hypocortisolism after only three doses of 
trilostane. The consistent lack of electrolyte abnormalities makes a mineralocorticoid 
deficiency highly unlikely but to formally demonstrate this aldosterone should have 
been measured on one or more of the samples obtained after ACTH stimulation as 
most reference ranges for aldosterone include very low concentrations. Unfortunately 
these samples were not retained for this analysis. The short duration of therapy and the 
different nature of the endocrine abnormality from the case of Chapman and others 
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(2004) makes this case report both new and of interest to any veterinarian who 
prescribes trilostane. The use of trilostane is increasing within Australia (Dechra 
Pharmaceuticals, data on file) and therefore similar cases may occur in the future. 
Although adrenal necrosis has only been previously reported as a complication of 
trilostane administration in one case, a syndrome of prolonged suppression of 
adrenocortical function in dogs receiving trilostane has been reported in abstract form.8, 
16 All of the dogs in this abstract did continue to require trilostane albeit at a lower dose. 
Although adrenal gland histopathology was not described in these cases, the 
syndrome may also represent a milder form of adrenal necrosis. 
The development of persistent isolated hypocortisolism and ultrasonographic changes 
in adrenal architecture cannot be explained by current knowledge of trilostane’s 
actions. It is known that the duration of action of trilostane is short.17 Although serum 
cortisol concentrations may be undetectable for a few hours after dosing, they quickly 
return to normal levels. This short term suppression of adrenocortical function generally 
provides good long-term control of hyperadrenocorticism in most patients.1 In some 
cases the drug is so short acting that the frequency of dosing has to be increased from 
once to twice daily.17 Recent work suggests that the effects of trilostane on 
steroidogenesis may not be limited to inhibition of the enzyme 3β hydroxysteroid 
dehydrogenase.18 However no data presented by Sieber-Ruckstuhl and her colleagues 
would explain the changes observed in this case or that of Chapman and his 
colleagues.  
The link between hypocortisolaemia and trilostane administration in this case is purely 
temporal. It is possible that this may have been a coincidence and other causes of 
adrenal necrosis are possible. Trilostane might cause adrenal necrosis by 
accumulating to toxic levels within the adrenocortical cells. Alternatively trilostane may 
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induce programmed cell death (apoptosis) as an idiosyncratic reaction in certain dogs 
without reaching cellular concentrations that would be considered toxic. The drug might 
also induce vascular changes or act in a haptogenic capacity to stimulate an adverse 
immune response. The pathological findings of Chapman and others are not consistent 
with these latter two theories. More dogs need to be studied and clinicians should be 
encouraged to submit adrenal glands from dogs that have died following any drug 
administration.  
It should be noted that ACTH administration has been associated with an increased 
risk of bilateral adrenal haemorrhagic necrosis in man and it alone may cause 
degeneration and focal necrosis of the adrenal cortex.19 Dogs frequently receive 
synthetic ACTH in the days before trilostane is dispensed and it is possible that this 
may be a contributing factor in some cases of adrenal necrosis. In this particular case 
the time delay from the diagnosis to the administration of trilostane was nearly 5 weeks 
and so synthetic ACTH is not likely to have been a factor. However it has been shown 
that dogs receiving trilostane show an increase in serum concentrations of endogenous 
ACTH.20 It is possible that the three doses of trilostane caused an immediate increase 
in endogenous ACTH and this lead to adrenal necrosis. 
Spontaneous remission of HAC has been reported previously and was presumed to 
result from embolisation of a pituitary microadenoma with subsequent normalisation of 
adrenal function.11 Few details are presented on the five dogs with this syndrome and it 
is not known if they developed temporary or permanent hypocortisolism, or if the 
suspected pituitary lesions were confirmed using advanced diagnostic imaging 
modalities or pathology, or if the adrenal glands were similarly examined. 
Clinicians should be aware that the response of dogs to trilostane is very variable. 
Many dogs require a change in dose (increase or decrease) and much higher doses 
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than the initial starting doses may be required in some cases.3 The efficacy of the drug 
has to be monitored in each patient and adjustments made as necessary. Veterinarians 
using trilostane should be aware that it may rarely cause adrenal gland necrosis and 
potentially acute iatrogenic hypoadrenocorticism or isolated hypocortisolism. 
Awareness of this complication will help to ensure a good prognosis. Despite this case 
report, trilostane should still be considered an effective and safe drug to use in the 
treatment of HAC. 
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Figures (to also be supplied separately) 
Figure 1 
Adrenal ultrasonograph from a 12 year old neutered male Miniature Poodle  performed 
at the time of diagnosis of hyperadrenocorticism. The cranial pole of the left adrenal (a) 
measured 7.8 mm, however the caudal pole was slightly smaller at 6.6 mm. The right 
adrenal (b) had a similar, plump appearance, and a slightly larger cranial pole (8.6 mm) 
compared to the caudal pole (6.4 mm). 
a) 
 
b) 
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Figure 2 
Adrenal ultrasonograph from a 12 year old neutered male Miniature Poodle performed 
at the time of diagnosis of isolated hypocortisolism. The cranial pole of the left adrenal 
(a) measured 3.8 mm and the caudal pole measured 4.2 mm The cranial pole of the 
right adrenal gland (b) measured 4.6 mm and the caudal pole 5.2 mm right adrenal  
a) 
 
b) 
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